 Qualigen Therapeutics Inc NASDAQ: QLGN shares are ticking lower as the company withdrew the FDA Emergency Use Authorization EUA application for its FastPack SARS-CoV-2 IgG diagnostic test for COVID-19 antibodies. According to the SEC filing, the EUA was submitted in June last year, and now the company believes it is no longer viable to launch the test. 